Meanwhile the experience with the new screen has grown again. I have been working intensively with the screen over the past few days and weeks and have also been able to use the screen right next to it to compare how the quality affects, for example, annotation work on digitized carcinoma specimens and I am once again enthusiastic - it really is a quantum leap...
Ultimate slide to eye confidence with our display for digital pathology
Meet MDPC-8127, our ultra-high definition medical grade monitor designed exclusively for digital pathology. With regulatory clearances for use in digital pathology including primary diagnosis, it’s the first display that you can confidently integrate into your digital pathology workflow with multiple whole slide imaging systems. Work with superior imaging technology and analyze your histological samples confidently, with unprecedented visual richness.
Our Alliance partners
*These products are currently not cleared for commercial distribution. The Nio 8MP is awaiting 510(k) clearance in the United States. The products are awaiting CE marking in Europe but also product registration in several other countries worldwide. For additional information, please get in touch with your Barco representative.
**In the USA the MDPC-8127 can be used with WSI scanners and viewing software that have been validated for use with the display.
The device may be used for primary diagnosis in the following validated FDA-cleared WSI systems and digital pathology viewing software:
- Philips Intellisite Pathology Solution with Philips Image Management System viewing software
- Philips Intellisite Pathology Solution with Paige.AI Inc. FullFocus DX viewing software
- Leica Aperio AT2 DX System with ImageScope DX viewing software
- Leica Aperio AT2 DX scanner with Sectra Digital Pathology Module
- Hamamatsu NanoZoomer S360MD slide scanner system
- Leica Aperio GT 450 DX scanner with Aperio WebViewer DX
Talk to us
Don't hesitate to contact us with your questions. Our team will gladly point you in the right direction.